Overcoming MCL-1-driven adaptive resistance to targeted therapies

Kris C Wood

doi:10.1038/s41467-020-14392-z

Overcoming MCL-1-driven adaptive resistance to targeted therapies

Nat Commun. 2020 Jan 27;11(1):531. doi: 10.1038/s41467-020-14392-z.

Author

Kris C Wood¹

Affiliation

¹ Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA. kris.wood@duke.edu.

Abstract

Two complementary studies in Nature Communications define a critical role for the anti-apoptotic protein MCL-1 as a driver of adaptive survival in tumor cells treated with oncogene targeted therapies, providing a rationale for combining these agents with newly developed MCL-1 inhibitors in the clinic.

Publication types

Comment

MeSH terms

Drug Resistance, Neoplasm
Humans
MAP Kinase Signaling System
Melanoma*
Myeloid Cell Leukemia Sequence 1 Protein
Proto-Oncogene Proteins B-raf*
Proto-Oncogene Proteins c-bcl-2

Substances

MCL1 protein, human
Myeloid Cell Leukemia Sequence 1 Protein
Proto-Oncogene Proteins c-bcl-2
BRAF protein, human
Proto-Oncogene Proteins B-raf